Clinical Trials Browser

Phase 1 × INDUSTRY × Thalidomide × Clear all

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 1 FDA

Multiple Myeloma

NCT02870036 2017-07-14

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms